drugset / Trial / NCT03501368
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
Phase 1
Completed
27 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the risks and benefits of ceritinib (ZYKADIA) given in combination with trametinib (MEKINIST) in patients who have progressed on prior melanoma therapy.
Timeline
- Start
- 2018-06-27
- Primary completion
- 2022-10-28
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ceritinib | Small molecule | 450 mg | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |